$75 Million

Mersana Therapeutics

Initial Public Offering

Bookrunner, June 2017

Mersana Therapeutics
Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need.